Prostate cancer is the second most common cancer among men. Despite advances in diagnosis and management, prostate cancer led to more than 300,000 deaths globally in 2020. Chemotherapy is a cornerstone of therapy for advanced prostate cancer and can prolong survival of patients with both castration-sensitive and castration-resistant disease. Herein, we present a comprehensive review of the data supporting implementation of chemotherapy in the modern treatment of advanced prostate cancer, with special attention to the use of chemotherapy for aggressive variant prostate cancer (e.g., neuroendocrine prostate cancer) and the combination of chemotherapy with androgen signaling inhibitors. As the field of prostate cancer research continues to rapidly evolve yielding novel agents and treatment modalities, chemotherapy continues to play an essential role in prolonging the survival of patients with advanced and metastatic prostate cancer.
前列腺癌是男性中第二大常见癌症。尽管诊断与管理手段不断进步，2020年全球仍有超过30万人死于前列腺癌。化疗是晚期前列腺癌治疗的基石，可延长去势敏感性及去势抵抗性疾病患者的生存期。本文系统综述了支持化疗在现代晚期前列腺癌治疗中应用的数据，特别关注化疗在侵袭性变异型前列腺癌（如神经内分泌前列腺癌）中的应用，以及化疗与雄激素信号抑制剂的联合治疗方案。随着前列腺癌研究领域持续快速发展，新型药物与治疗模式不断涌现，化疗在延长晚期及转移性前列腺癌患者生存方面仍发挥着不可或缺的作用。
Current Trends in Chemotherapy in the Treatment of Metastatic Prostate Cancer
肿瘤(癌症)患者之家